Continuous glucose monitor
A continuous glucose monitor (CGM) is a wearable glucose-sensing technology used to measure interstitial glucose levels repeatedly over time, providing a dense glucose profile rather than isolated point measurements.
A continuous glucose monitor (CGM) is a wearable glucose-sensing technology used to measure interstitial glucose levels repeatedly over time, providing a dense glucose profile rather than isolated point measurements. In clinical practice, CGM is used to support diabetes management by helping patients and clinicians identify patterns of hyperglycemia and hypoglycemia, assess glycemic variability, and evaluate metrics such as time-in-range, time-above-range, and time-below-range.
CGM has become an important tool in the management of type 1 diabetes and is increasingly studied in type 2 diabetes, including in people treated with basal insulin, insulin therapy, and modern therapies. It is also being explored in other metabolic and endocrine contexts, such as cystic fibrosis-related diabetes, glycogen storage disease, post-bariatric hypoglycemia, and in people without diabetes for research on early dysglycemia and personalized nutrition. Recent work also links CGM with automated insulin delivery systems, hybrid closed-loop systems, fully closed-loop insulin delivery, and CGM-integrated digital health apps, reflecting its central role in contemporary diabetes technology.
Where the papers sit
10 papers from the last 6 months study continuous glucose monitor directly · updated from PubMed 12 Oct 2026
Study type 1 clinical trial · 5 observational · 3 human data · 1 unclassified
Themes 3 themes · 1 paradigm shift
-
Diabetes Monitoring and Care
Glycemic monitoring is moving from specialist use toward integrated diabetes care across type 1 and type 2 diabetes. Primary-care alarm integration, telemonitoring and electronic health records are being used to support follow-up and glycemic control. Glycated albumin and CGM are being compared for identifying microvascular risk. Procurement costs and regional variation in pump and CGM use remain important barriers.
5 papers · 50%
-
CGM Accuracy and Validation
Real-time CGM is being evaluated against self-monitoring, HbA1c and fasting plasma glucose across clinical and population settings. Accuracy work relies on mean absolute relative difference, Clarke Error Grid performance and agreement thresholds. Pediatric studies add safety and usability to the validation question. The field is extending from glucose measurement toward prediabetes classification, while the clinical value of discordant measures remains open.
3 papers · 30%
-
Automated Insulin Delivery Access
Automated insulin delivery is being assessed alongside the practical question of who can obtain and sustain diabetes technology. Prior-authorization policies and Medi-Cal coverage directly shape access in underserved populations. Economic evaluation, including Control-IQ+ in insulin-treated type 2 diabetes, is being used to support broader adoption. The field is linking technology effectiveness with affordability and insurance policy rather than treating access as separate from care.
2 papers · 20%
CGM metrics do not replace laboratory glycemic markers
The large real-world cohort study of prediabetes classification and the type 2 diabetes study of microvascular complications both found that CGM-derived measures were insufficient as standalone assessments. In 1,883 participants, no single CGM metric achieved high performance for prediabetes classification, while in 3,251 people with type 2 diabetes, glycated albumin remained independently associated with retinopathy, kidney disease, and composite microvascular complications even after adjustment for time in range. The assumption that CGM metrics can substitute for conventional glycemic markers therefore gives way to a multimarker approach in which laboratory measures retain distinct diagnostic and prognostic value 42349688Jun 42289190Jun.
Papers
The 10 papers from the last 6 months that study continuous glucose monitor directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Diabetes Monitoring and Care (5)
- Cost-effective procurement and prescribing of continuous glucose monitors in the NHS. British journal of nursing (Mark Allen Publishing) · 5 Aug 2026 PMID 42555595
- Trends of insulin pump therapy and continuous glucose monitoring use among people with type 1 diabetes by institution and region in Japan during 2014 and 2022: an observational study using nationwide claims data. Diabetes research and clinical practice · 27 Jul 2026 PMID 42508497
- Study confirms benefits of continuous glucose monitoring in type 2 diabetes. Drug and therapeutics bulletin · 16 Jun 2026 PMID 42303377
- Complementary value of glycated albumin and continuous glucose monitoring for assessing microvascular complications in type 2 diabetes. Diabetes research and clinical practice · 14 Jun 2026 PMID 42289190
- Integrating continuous glucose monitoring alarms in primary care: Evaluation of utilization rates and achieved glycemic control in people with type 2 diabetes treated with insulin. Primary care diabetes · 28 Apr 2026 PMID 42049539
CGM Accuracy and Validation (3)
- Accuracy, safety, and usability of a real-time continuous glucose monitoring system in pediatric diabetes management. Journal of diabetes investigation · 13 Aug 2026 PMID 42593090
- Continuous glucose monitoring for prediabetes classification in a large real-world cohort: Comparison with HbA1c and fasting plasma glucose. Diabetes research and clinical practice · 25 Jun 2026 PMID 42349688
- Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial. The lancet. Diabetes & endocrinology · 26 Apr 2026 PMID 42035781
Automated Insulin Delivery Access (2)
- Impact of Prior Authorization Suspension on Access to Diabetes Technology in an Underserved Population: A Retrospective Analysis. Diabetes care · 18 Jun 2026 PMID 42312902
- Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States. Diabetes, obesity & metabolism · 5 May 2026 PMID 42086278
By study type
Clinical trials (1)
- Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial. The lancet. Diabetes & endocrinology · 26 Apr 2026 PMID 42035781
Observational studies and case reports (5)
- Accuracy, safety, and usability of a real-time continuous glucose monitoring system in pediatric diabetes management. Journal of diabetes investigation · 13 Aug 2026 PMID 42593090
- Trends of insulin pump therapy and continuous glucose monitoring use among people with type 1 diabetes by institution and region in Japan during 2014 and 2022: an observational study using nationwide claims data. Diabetes research and clinical practice · 27 Jul 2026 PMID 42508497
- Continuous glucose monitoring for prediabetes classification in a large real-world cohort: Comparison with HbA1c and fasting plasma glucose. Diabetes research and clinical practice · 25 Jun 2026 PMID 42349688
- Impact of Prior Authorization Suspension on Access to Diabetes Technology in an Underserved Population: A Retrospective Analysis. Diabetes care · 18 Jun 2026 PMID 42312902
- Integrating continuous glucose monitoring alarms in primary care: Evaluation of utilization rates and achieved glycemic control in people with type 2 diabetes treated with insulin. Primary care diabetes · 28 Apr 2026 PMID 42049539
Human data, design not indexed (3)
- Cost-effective procurement and prescribing of continuous glucose monitors in the NHS. British journal of nursing (Mark Allen Publishing) · 5 Aug 2026 PMID 42555595
- Study confirms benefits of continuous glucose monitoring in type 2 diabetes. Drug and therapeutics bulletin · 16 Jun 2026 PMID 42303377
- Complementary value of glycated albumin and continuous glucose monitoring for assessing microvascular complications in type 2 diabetes. Diabetes research and clinical practice · 14 Jun 2026 PMID 42289190
Unclassified: not yet indexed with MeSH (1)
- Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States. Diabetes, obesity & metabolism · 5 May 2026 PMID 42086278
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.